JAZZ Jazz Pharmaceuticals plc

Jim Cramer offered mixed assessments of five stocks during CNBC’s “Mad Money” Lightning Round, highlighting opportunities in pharmaceuticals while warning about interest-rate risks and reassessing a potential takeover scenario. Cramer expressed support for Jazz Pharmaceuticals, saying he was willing to invest despite the stock’s speculative nature. He noted that the company is profitable, suggesting its financial performance provides some support for the investment case even as uncertainty remains. Jazz shares were trading at $218.42, down 1.81% during Friday’s session. Cramer also revisited EchoStar after a report suggested that SpaceX could make a takeover bid for the satellite communications company. Although he had previously been skeptical of EchoStar, he said the potential transaction was compelling enough that he could not ignore it. However, the report did not confirm that SpaceX had made a formal offer, leaving the possibility speculative. $JAZZ $APLE $ECHO $SPCX

Record quarter doing the talking for $JAZZ imo up about 8.6% near 232.94 after Q3 revenue hit a record 1.243 billion, up about 10% year over year oncology grew 35% year over year, Xywav sales rose 12% to 483 million, and Zepzelca jumped 32% to 104 million Ziihera is just getting started in first line HER2 positive gastroesophageal cancer, 21 million in its debut quarter, with new ordering accounts tripling in September versus August guidance got raised as well, full year now 4.775 billion to 4.85 billion. fading this print looks early ngl

$JAZZ Okay, fair enough. it got stuck at 135-150. Let's find some buyers at 110! No need to drift lower. Top quality stock. Under 200 a great bargain, if it comes to that....

$JAZZ nine month acquired research charges add up in Note 2 in a way the release never splits. Actio was 754.2 million dollars of the 831.2 million total, AbCellera added 56 million and Werewolf added 21 million, and Actio alone carried 850.7 million dollars of total consideration.

$JAZZ reported earnings today after the close and beat EPS estimates with a smaller loss: -$3.88 adjusted EPS vs -$4.05 expected, according to Stock Meadow.

$JAZZ Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$3.88 down -147.72% YoY • Reported revenue of $1.24B up 10.38% YoY • Jazz Pharmaceuticals expects total revenues in 2026 to increase compared to 2025; cost of product sales to be in line, SG&A to decrease, and R&D expenses to increase compared to 2025.

$JAZZ reports earnings today after the close. I used Stock Meadow's earnings dashboard to review its history: JAZZ has beaten EPS estimates in 4 of its last 8 reports.